NervGen Pharma (NASDAQ:NGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

NervGen Pharma (NASDAQ:NGEN) has received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, one has assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $18.00.

Several analysts have issued reports on NGEN shares. TD Cowen started coverage on NervGen Pharma in a research note on Thursday. They issued a “buy” rating for the company. Zacks Research raised NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Wall Street Zen raised NervGen Pharma from a “sell” rating to a “hold” rating in a research note on Friday, May 29th. Finally, Weiss Ratings started coverage on NervGen Pharma in a research note on Friday, April 24th. They issued a “sell (d-)” rating for the company.

NervGen Pharma Trading Down 4.4%

Shares of NGEN opened at $1.73 on Thursday. NervGen Pharma has a 1 year low of $1.70 and a 1 year high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last issued its earnings results on Friday, May 15th. The company reported $999.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $999.07.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.